1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6A61C8406E65E38126525843C0027F731
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/patient-advocacy-2020-how-top-pharma-companies-shape-policy-improve-access-boost-patient-voice-outside-united-states
18
19
203.93.75.30
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25BMR




Products & Services Marketing Management Patient Advocacy

Patient Advocacy 2020: How Top Pharma Companies Partner with Advocacy Groups to Shape Policy, Improve Access, and Boost Patient Voice Outside of the United States

ID: PSM-357


Features:

51 Info Graphics

23 Data Graphics

270+ Metrics

40 Narratives


Pages: 89


Published: 2019


Delivery Format: Shipped


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
As the pharmaceutical industry gravitates toward a patient centric model, the importance of establishing meaningful relationships with advocacy groups has never been greater for organizations.

Best Practices, LLC conducted benchmarking research to highlight effective practices in patient advocacy group collaboration and relationship management outside of the United States.

This report examines ideal structures and skill sets for pharma groups that deal with advocacy groups, investment and resource levels, regulatory impact, top challenges, and emerging trends that will define the future of successful manufacturer-advocacy collaboration.

Industries Profiled:
Pharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Clinical Research; Research; Health Care; Communications; Medical; Biopharmaceutical; Laboratories


Companies Profiled:
AbbVie; Astellas; Bayer; BioMarin; Bionical Emas; Bluebird Bio; Covance; Janssen; Lundbeck; Merck; MSD; NexGen Healthcare Communications; Novartis; Parkway Pantai; Sanofi; Servier; Shire; Spark Therapeutics; Takeda Pharmaceuticals; Teva Pharmaceutical Industries Ltd; Tillotts Pharma; UCB Pharma; The Mexican Organization for Rare Disorders (OMER)

Study Snapshot

Best Practices, LLC engaged 26 leaders supporting patient advocacy at 23 life sciences companies through a benchmarking survey. Benchmark partners represent groups that operate outside of the United States.


Key topics covered in this report include:

  • Understanding the “advocacy” landscape outside of the United States
  • Effective practices for working with potentially hostile patient advocacy groups
  • Preferred advocacy structures
  • Advocacy tools
  • Core competencies of advocacy professionals
  • Advocacy lessons learned from socially sensitive or stigmatized disease areas
  • Profiling advocacy group experience & expertise


Key Findings

Select key insights uncovered from this report are noted below. Detailed findings are available in the full report.

  • Structuring high performance pharma advocacy groups: There is no one-size-fits-all approach to structure pharma patient advocacy groups. Nearly half of the benchmark class has adopted centralized structure followed by decentralized structure at 27% companies and hybrid structure at 23%.

  • Evolving regulatory environment is challenging patient advocacy: Changing regulations are also affecting the patient advocacy landscape. Groups are increasingly getting involved with the FDA. In fact, 76% of partners believe the latest changes in regulations will have high-to-medium impact on patient advocacy strategies. Increasing patient centricity, enabling ease of access, collaborating, and preparing clinical teams will help companies address these regulatory changes.

  • New technologies for patient education: Video sites, social networks, professional networks, and podcasts have created new channels and opportunities for pharma and external advocacy groups to educate patients. This study reveals that around 80% of participants rated social network groups like Facebook and YouTube & other video sites as important.

Table of Contents

I.
Overviewpgs. 3-11
Research Overviewpg. 4
Universe of Learningpg. 5
Pharmaceutical Advocacypg. 6
Key Recommendationspg. 7
Key Findingspgs. 8-11
II.
Patient Advocacy Functional Structurepgs. 12-21
III.
Patient Advocacy Partner Coordination & Effectivenesspgs. 22-25
IV.
Developing & Optimizing Patient Advocacy Partnershipspgs. 26-30
V.
Managing Relationships Within Controversial Disease Statespgs. 31-39
VI.
Current Trends & Future Directionspgs. 40-44
VII.
Regulatory Impact on Patient Advocacypgs. 45-51
VIII.
Use of Technology, Future Trends & Issuespgs. 52-56
IX.
Ethics and Patient Advocacy Relationspgs. 57-60
X.
Lessons Learnedpgs. 61-69
XI.
Participants’ Profilepgs. 70-72
XII.
Appendixpgs. 73-88
XIII.
About Best Practices, LLCpg. 89

    List of Charts & Exhibits


    I. Patient Advocacy Functional Structure

    • Structure of company’s patient advocacy function
    • Efficacy of current structure of patient advocacy function
    • Optimal structure for an internal patient advocacy group with reasons
    • Interview narrative around company-sponsored summits
    • Ensuring that patient advocacy organizations may properly contact or communicate with your company’s patient advocacy functional personnel
    • Interview narratives on using Medical Affairs as a contact point
    • Estimated number of FTEs dedicated to patient advocacy activities
    • Patient advocacy experience of benchmark partners
    • Number of patient advocacy groups currently supported by benchmark companies and expected to support in the coming year

    II. Patient Advocacy Partner Coordination & Effectiveness

    • Effective metrics for measuring the success of patient advocacy activities and relationships
    • Effective approaches designed to build relationships with patient advocacy groups
    • Effective methods for prioritizing objectives when a patient advocacy group maintains relationships with multiple brands or therapeutic areas

    III. Developing & Optimizing Patient Advocacy Partnerships

    • Importance of patient advocacy collaborations at different lifecycle stages
    • Most important forms of education, program support, and grants/sponsorships during each of the four key lifecycle stages
    • Effective approaches to seed early advocacy relationships
    • Effective strategies for gaining early-stage support with advocacy groups

    IV. Managing Relationships Within Controversial Disease States

    • Interview narrative around demonstrating the benefits of a collaborative relationship to advocacy groups
    • Most critical considerations when managing collaboration with an advocacy group regarding therapies that may trigger controversy or social stigma
    • Interview narrative around education being a key element when working in areas with a social stigma
    • Most effective approaches in educating the market on conditions that may be highly controversial or have a social stigma
    • Special interest groups’ impact
    • Interview narrative around transparency being key to collaborating on social stigma disease areas
    • Most effective strategies and tactics in minimizing opposition from patient advocacy or other special interest groups against a therapy that could be considered controversial
    • Interview narrative around listening to external partners for achieving success with advocacy groups

    V. Current Trends & Future Directions

    • Interview narrative around developing an advocacy approach depending upon the maturity level of a patient advocacy group
    • Current factors in the marketplace that should receive the greatest consideration with respect to patient advocacy issues
    • Interview narrative around working on the overall negative attitude toward pharma companies
    • Interview narrative around taking inputs into development process from patient advocacy groups

    VI. Regulatory Impact on Patient Advocacy

    • Interview narrative around patient groups’ involvement in drug development
    • Interview narrative around engagement of patient groups in many aspects of clinical studies
    • Funding of clinical trial studies by patient advocacy groups
    • Impact of new regulations on patient advocacy strategies and tactics to address them
    • Interview narrative around patient groups’ interaction with regulatory agencies
    • Impact of patient involvement in government regulatory agencies, including the FDA and the Prescription Drug User Fee Act on advocacy initiatives within benchmark companies

    VII. Use of Technology, Future Trends & Issues

    • Importance of listed platforms in delivering education to patient groups
    • Issues or opportunities foreseen as important for patient advocacy over the next 3 years
    • Interview narrative around understanding external group’s perspective to create effective advocacy relationship
    • Maintaining robust relationships with existing advocacy groups, while also expanding to regional groups and providing strong support to national policies

    VIII. Ethics and Patient Advocacy Relations

    • Interview narrative around abiding to ethical boundaries when interacting with patient groups
    • Ethical boundaries adhered to while working with patient advocacy groups
    • Interview narrative on the do’s and don’ts for effective advocacy relationships

    IX. Lessons Learned

    • Interview narrative: Not all patient advocacy groups are effective organizations
    • Most “painful” lessons learned by benchmark partners about relationships with patient advocacy groups
    • Interview narrative around one of the biggest concerns that external cancer advocacy groups have and one of the ways to mitigate it
    • Top success stories about relationships with patient advocacy groups
    • Interview narrative around working with competitors to advance patient welfare
    • Interview narrative around building relations
    • Interview narrative: Patient groups are not always effective in the policy-making process
    • Additional insights in patient advocacy

    X. Participants’ Profile

    • Demographics of benchmark partners
    • Therapeutic area represented by benchmark partners

    XI. Appendix

    • Voices from the field: Optimal structure for an internal patient advocacy group along with reasons
    • Voices from the field: Organization of patient advocacy in a formal structure and improving the structure
    • Voices from the field: Organization of patient advocacy in an informal structure and improving the structure
    • Voices from the field: Top collaboration issues when working with socially sensitive diseases
    • Voices from the field: Best approaches to minimize opposition from special interest groups
    • Voices from the field: Current issues challenging patient advocacy
    • Voices from the field: Impact of new regulations and addressing them
    • Voices from the field: Patient involvement in government regulatory agencies
    • Voices from the field: Future patient advocacy issues and opportunities
    • Voices from the field: Patient advocacy, religious or other special interest groups having a greater impact
    • Voices from the field: Ethical boundaries while working with patient advocacy groups
    • Voices from the field: Painful lessons learned about relationships with patient advocacy groups
    • Voices from the field: Success stories about relationships with patient advocacy groups
    • Voices from the field: Benchmark partners’ experience in working with patient advocacy groups